Apotex
GenericsApotex is a generic drug manufacturer focused on Cardiovascular, Neurology, Oncology. Key products include IVRA.
Apotex's Key Drugs
Apotex's core commercial portfolio centers on AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.
Hypertension
Glaucoma
Hypertension
Multiple Myeloma
Seasonal Allergic Rhinitis
Apotex's Recent FDA Approvals
Apotex secured 5 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
Apotex's Therapeutic Areas
Apotex's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 4 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Apotex's Top Competitors
Apotex's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and GE HEALTHCARE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Apotex Pipeline Snapshot
Active clinical trials for Apotex across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (13)
Discontinued (3)
Company Info
- First Approval
- 1964-01-17
- Latest
- 2026-06-18
- Applications
- 383